MX2009012124A - Compuestos terapeuticos estereoisomeros de propofol. - Google Patents

Compuestos terapeuticos estereoisomeros de propofol.

Info

Publication number
MX2009012124A
MX2009012124A MX2009012124A MX2009012124A MX2009012124A MX 2009012124 A MX2009012124 A MX 2009012124A MX 2009012124 A MX2009012124 A MX 2009012124A MX 2009012124 A MX2009012124 A MX 2009012124A MX 2009012124 A MX2009012124 A MX 2009012124A
Authority
MX
Mexico
Prior art keywords
propofol
stereoisomers
therapeutic compounds
formula
anesthetic
Prior art date
Application number
MX2009012124A
Other languages
English (en)
Inventor
Thomas E Jenkins
Original Assignee
Pharmacofore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacofore Inc filed Critical Pharmacofore Inc
Publication of MX2009012124A publication Critical patent/MX2009012124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C07C37/0555—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un estereoisómero (-) de fórmula (I): (fórmula I), en donde X es H o F; o una sal o un profármaco de él aceptable farmacéuticamente, útil como anestésico.
MX2009012124A 2007-05-09 2008-05-08 Compuestos terapeuticos estereoisomeros de propofol. MX2009012124A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92842907P 2007-05-09 2007-05-09
US92829607P 2007-05-09 2007-05-09
US92832707P 2007-05-09 2007-05-09
PCT/US2008/063082 WO2008141097A2 (en) 2007-05-09 2008-05-08 Stereoisomers propofol therapeutic compounds

Publications (1)

Publication Number Publication Date
MX2009012124A true MX2009012124A (es) 2010-02-18

Family

ID=39798084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012124A MX2009012124A (es) 2007-05-09 2008-05-08 Compuestos terapeuticos estereoisomeros de propofol.

Country Status (23)

Country Link
US (4) US8071818B2 (es)
EP (4) EP2146946B1 (es)
JP (1) JP5651009B2 (es)
KR (1) KR20100017436A (es)
CN (1) CN101715437B (es)
AT (1) ATE487685T1 (es)
AU (1) AU2008251482C1 (es)
BR (1) BRPI0811220A2 (es)
CA (1) CA2685570A1 (es)
DE (1) DE602008003431D1 (es)
DK (2) DK2301908T3 (es)
ES (1) ES2501592T3 (es)
HK (2) HK1138829A1 (es)
HR (1) HRP20140896T1 (es)
IL (1) IL201795A0 (es)
MX (1) MX2009012124A (es)
NZ (1) NZ580752A (es)
PL (2) PL2301908T3 (es)
PT (1) PT2146946E (es)
RU (1) RU2470908C2 (es)
SI (1) SI2301908T1 (es)
WO (1) WO2008141097A2 (es)
ZA (1) ZA201007603B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141097A2 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Stereoisomers propofol therapeutic compounds
JP5924539B2 (ja) * 2010-08-03 2016-05-25 学校法人 久留米大学 実験用小動物の脳波測定用装置及び脳波測定方法
CN102731265B (zh) * 2012-06-12 2014-12-10 四川百利药业有限责任公司 一种高纯度丙泊酚的制备方法
US11331271B2 (en) * 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
RU2635532C1 (ru) * 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
CN115708819A (zh) * 2022-11-24 2023-02-24 中国科学院深圳先进技术研究院 丙泊酚的抗焦虑制药用途及抗焦虑药物制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US237213A (en) 1881-02-01 William j
US2747982A (en) 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
SU1525139A1 (ru) * 1987-11-10 1989-11-30 Куйбышевский политехнический институт им.В.В.Куйбышева Способ получени о-втор-бутилфенола
ES2087019B1 (es) * 1994-02-08 1997-03-16 Bobel246 S L Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
EP1161226B1 (en) 1999-02-18 2004-05-26 SuperGen, Inc. Phosphocholine linked prodrug derivatives
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2002028411A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
RU2316317C2 (ru) 2001-12-28 2008-02-10 Эм-Джи-Ай Джи-Пи, Инк. Составленные на основе воды фармацевтические композиции водорастворимых пролекарств пропофола
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
KR20070087004A (ko) 2002-04-08 2007-08-27 엠쥐아이 쥐피, 아이엔씨. 프로포폴의 수용성 프로드럭을 함유하는 약제학적 조성물및 그것을 투여하는 방법
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
DE20215415U1 (de) 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
ZA200504940B (en) 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US7230003B2 (en) 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US20070043121A1 (en) * 2003-09-29 2007-02-22 Brown Milton L Discovery of novel soluble crystalline anesthetics
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
EP1791521A4 (en) 2004-09-17 2009-10-21 Eisai Corp North America METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE
CA2586410A1 (en) 2004-12-23 2006-07-06 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel
AU2006328198B2 (en) * 2005-12-19 2013-07-18 Medizinische Hochschule Hannover Substituted phenol derivatives as analgesics
US7535698B2 (en) 2006-03-07 2009-05-19 Panasonic Corporation Case, portable information equipment using the same and manufacturing method of the case
US7731356B1 (en) 2006-07-24 2010-06-08 Daniel Ayers Gilbert Hanging eyeglasses
EP2152651B1 (en) 2007-05-09 2012-01-04 Pharmacofore, Inc. Therapeutic compounds
WO2008141097A2 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Stereoisomers propofol therapeutic compounds

Also Published As

Publication number Publication date
CN101715437B (zh) 2013-06-12
NZ580752A (en) 2012-03-30
WO2008141097A3 (en) 2008-12-31
BRPI0811220A2 (pt) 2014-10-29
PL2301908T3 (pl) 2015-02-27
CN101715437A (zh) 2010-05-26
EP2146946A2 (en) 2010-01-27
US8242315B2 (en) 2012-08-14
CA2685570A1 (en) 2008-11-20
HK1156019A1 (en) 2012-06-01
DE602008003431D1 (de) 2010-12-23
US20140206773A1 (en) 2014-07-24
ZA201007603B (en) 2012-08-29
AU2008251482A1 (en) 2008-11-20
DK2301908T3 (da) 2014-09-15
HRP20140896T1 (hr) 2015-01-02
HK1138829A1 (en) 2010-09-03
EP2146946B1 (en) 2010-11-10
EP2301908B8 (en) 2014-09-03
JP2010526826A (ja) 2010-08-05
US8575400B2 (en) 2013-11-05
US20100292346A1 (en) 2010-11-18
EP2810927A1 (en) 2014-12-10
PL2146946T3 (pl) 2011-04-29
AU2008251482B2 (en) 2013-09-26
IL201795A0 (en) 2010-06-16
ES2501592T3 (es) 2014-10-02
KR20100017436A (ko) 2010-02-16
RU2470908C2 (ru) 2012-12-27
WO2008141097A2 (en) 2008-11-20
DK2146946T3 (da) 2011-02-14
PT2146946E (pt) 2011-02-14
US20130059919A1 (en) 2013-03-07
US8071818B2 (en) 2011-12-06
EP2301908A1 (en) 2011-03-30
US20120035271A1 (en) 2012-02-09
US8871815B2 (en) 2014-10-28
ATE487685T1 (de) 2010-11-15
JP5651009B2 (ja) 2015-01-07
RU2009145537A (ru) 2011-06-20
AU2008251482C1 (en) 2014-04-03
EP2292577A1 (en) 2011-03-09
SI2301908T1 (sl) 2014-10-30
WO2008141097A9 (en) 2009-04-02
EP2301908B1 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
MX2009012125A (es) Compuestos terapeuticos.
TNSN08407A1 (en) Organic compounds
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TW200728307A (en) Novel spirochromanone derivatives
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
TW200833675A (en) Nicotinamide derivatives
GB0607954D0 (en) Organic compounds
TN2012000248A1 (en) Novel spiropiperidine compounds
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
TW200612958A (en) Substituted imidazole derivatives
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
MY187718A (en) Pharmaceutical formulations
WO2007084728A3 (en) 2-imino-benzimidazoles
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MX2010004669A (es) Proceso para la preparacion de derivados de isoindol asi como tambien un proceso para la preparacion de sus intermediarios.
MX2009005071A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
MX2011011776A (es) Nuevos profarmacos de triptolite.
MX2009012124A (es) Compuestos terapeuticos estereoisomeros de propofol.
TNSN08369A1 (en) Benzimidazole derivatives
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: HYDROGEN ENERGY INTERNATIONAL LIMITED.*

GB Transfer or rights
PD Change of proprietorship

Owner name: SOWOOD HEALTHCARE LLC